Nuformix (NFX) News Today GBX 0.05 0.00 (0.00%) (As of 11/22/2024 10:31 AM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitors All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Nuformix plc (NFX.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comNuformix Share Chat (NFX)September 17, 2024 | lse.co.ukNuformix plc (NFX.L)September 15, 2024 | ca.finance.yahoo.comNuformix PLC NFXNovember 16, 2023 | morningstar.comNuformix gets patent in Japan for pulmonary fibrosis treatment NXP002October 23, 2023 | lse.co.ukNuformix to fund its unlicensed programs with NXP001 windfallOctober 5, 2023 | finance.yahoo.comCloud Village Inc (9899)July 25, 2023 | uk.investing.comK Seng Seng Corporation Bhd (KSSC)July 15, 2023 | uk.investing.comSuzumo Machinery Co Ltd (6405)July 14, 2023 | uk.investing.comENGAGE XR Holdings PLC (EXRE)July 13, 2023 | uk.investing.comNuformix raises GBP70,000 to fund NXP002 programmeApril 17, 2023 | lse.co.ukNuformix Raises GBP70,000 in Discount Share SubscriptionApril 17, 2023 | marketwatch.comNuformix Says Study Shows Effectiveness of New Lung-Disease Treatment CandidateMarch 27, 2023 | marketwatch.comNuformix to Change Financial Year End to Sept. 30March 13, 2023 | marketwatch.comNuformix Shares Rise on Positive Olaparib Cancer Treatment Study ResultsDecember 20, 2022 | marketwatch.comNuformix delighted as NXP004 testing exceeds its expectationsDecember 20, 2022 | proactiveinvestors.com.auNuformix interim loss virtually flat as continues work on drugsDecember 13, 2022 | lse.co.ukNuformix to Start New NXP002 Study Program; Cancels Current Human IPF Tissue StudySeptember 23, 2022 | marketwatch.comLONDON MARKET EARLY CALL: Soft end to rocky week; UK retail sales dueSeptember 17, 2022 | lse.co.ukNuformix Shares Rise on Completion of Pre-Clinical Tolerability Studies for NXP002 TreatmentAugust 10, 2022 | marketwatch.comNuformix 1H Pretax Loss Narrowed on Lower Costs; Shares RiseJuly 28, 2022 | marketwatch.comNuformix to Continue Investigating NXP002 TreatmentJune 27, 2022 | marketwatch.comNuformix Executive Chair Alastair Riddell resigns after one yearMay 31, 2022 | lse.co.ukNuformix chairman resigns to take up new roleMay 31, 2022 | ca.proactiveinvestors.comNuformix Shares Drop After NXP002 Trial Results Were Inconsistent, Failure to Identify New ChiefMay 30, 2022 | marketwatch.comNuformix updates on NXP002, drug pipeline and CEO searchMay 30, 2022 | ca.proactiveinvestors.comNuformix will receive a gross £1.32mln from second tranche of Lanstead funding agreementApril 12, 2022 | proactiveinvestors.comNuformix Shareholder Raises Stake to 16.6%April 5, 2022 | marketwatch.comNuformix Investor Subscription to Raise GBP1.7 Mln for Product DevelopmentDecember 14, 2021 | marketwatch.comNuformix 1H Loss Narrowed Slightly on Lower CostsDecember 14, 2021 | marketwatch.comNuformix Shares Rise on Positive Trial StudiesNovember 25, 2021 | marketwatch.comNuformix Files New Patent Application for Cancer TreatmentNovember 12, 2021 | marketwatch.comCORRECT: Nuformix Chair Alastair Riddell to move to executive chairNovember 9, 2021 | lse.co.ukChill Brands Share ChatOctober 21, 2021 | lse.co.ukLONDON BRIEFING: AB Foods says Primark sales growth hit by 'pingdemic'September 14, 2021 | lse.co.ukNuformix Shares Rise on Global Agreement for Cancer-Drug LicenseSeptember 13, 2021 | marketwatch.comNo knee jerk reaction from Nuformix over CEO resignationJuly 23, 2021 | proactiveinvestors.comEXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departsJuly 22, 2021 | lse.co.uk Get Nuformix News Delivered to You Automatically Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter. Email Address First JFK… next Elon? (Ad)Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger. I share with you in this special investigative documentary. NFX Media Mentions By Week NFX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NFX News Sentiment▼0.000.49▲Average Medical News Sentiment NFX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NFX Articles This Week▼03▲NFX Articles Average Week Get Nuformix News Delivered to You Automatically Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PYC News ONT News GNS News OXB News PRTC News BVXP News ARIX News AVCT News HVO News FARN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:NFX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuformix plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuformix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
